TrialThe oncologist2025

Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study.

Tomasz M Beer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.